The Future of Clinical Trials: The Collaborative CTMS - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
The Future of Clinical Trials: The Collaborative CTMS

Source: Applied Clinical Trials

What is a Collaborative CTMS?
Traditionally, clinical trial management systems (CTMS) have been designed as stand-alone applications for either research sites or for organizations that multi-site research, including CROs, SMOs, AMCs, provider networks and many others. However, it has become apparent in the research community that there is a need for collaboration between these two types of systems. Collaboration can be as simple as pushing study protocols from one system to another, all the way through a fully-integrated platform with complete bi-directional exchange of information. The greater the level of collaboration, the more benefits researchers will see.

Why is it Important?
Studies succeed or fail at the site. Without sites, it would be nearly impossible to get new drugs and devices to market. Improving communication between sites and sponsor organizations with collaborative CTMS applications is important because it benefits everybody involved in the research process.

Benefits Derived
A collaborative CTMS generates dozens of unique benefits for organizations using such a system. Streamlining the interaction between all of the parties involved in a clinical trial leads to faster turnarounds, more complete data and a better picture of what is taking place in any particular study at any particular location. With the cost of bringing new drugs to the market constantly increasing, it is critical to reduce costs wherever possible. Effective collaboration can help organizations save money while conducting research by eliminating wasted time, preventing costly errors and ensuring accurate billing and financial tracking.


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here